Witkowska-Patena Ewa, Mazurek Andrzej, Dziuk Mirosław
Department of Nuclear Medicine, Military Institute of Medicine, Warsaw, Poland.
Affidea Mazovian PET/CT Centre, Warsaw, Poland.
Cent European J Urol. 2017;70(1):37-43. doi: 10.5173/ceju.2017.947. Epub 2017 Jan 11.
Prostate cancer (PCa) is a major health concern worldwide with up to 60% of patients experiencing biochemical relapse after radical treatment. Early diagnosis of PCa recurrence is of high importance for successful salvage therapy. The need for accurate imaging has prompted the introduction of prostate-specific membrane antigen (PSMA)-based radiotracers for positron emission tomography (PET).
In this review we summarized and discussed the results of the studies analyzing the utility of 68Ga-PSMA PET/CT in patients who experienced a biochemical relapse of prostate cancer.
PSMA-based PET scans have been proved to provide a superior diagnostic performance over other modalities for localization of the site of early PCa recurrence. 68Ga-PSMA has been also shown to have a higher sensitivity and specificity than other established PET radiotracers such as radiocholines.
The early studies show promising results and support the use of 68Ga-PSMA for PCa restaging. However, the number of studies concerning the utility of 68Ga-PSMA PET in the context of secondary PCa staging is limited and there is still a considerable scope for further research in this field.
前列腺癌（PCa）是全球主要的健康问题，高达60%的患者在根治性治疗后会出现生化复发。早期诊断PCa复发对于成功的挽救治疗至关重要。对精确成像的需求促使引入了基于前列腺特异性膜抗原（PSMA）的放射性示踪剂用于正电子发射断层扫描（PET）。
在本综述中，我们总结并讨论了分析68Ga-PSMA PET/CT在前列腺癌生化复发患者中的应用的研究结果。
基于PSMA的PET扫描已被证明在定位早期PCa复发部位方面比其他方法具有更高的诊断性能。68Ga-PSMA也已显示出比其他已确立的PET放射性示踪剂（如放射性胆碱）具有更高的敏感性和特异性。
早期研究显示出有前景的结果，并支持使用68Ga-PSMA进行PCa再分期。然而，关于68Ga-PSMA PET在继发性PCa分期中的应用的研究数量有限，该领域仍有相当大的进一步研究空间。
